Anthony J. Furlan, MD Medical Director, Cerebrovascular Center, Section of Stroke and Neurocritical Care, Department of Neurology, The Cleveland Clinic Foundation
Address: Anthony J. Furlan, MD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Dr. Furlan has indicated that he has received grant or research support from the Possis corporation, serves as a consultant for the Abbott and Lilly corporations, and is on the speakers’ bureau of the Bristol-Myers Squibb corporation.
This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.
Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.
ABSTRACTAlthough intravenous tissue plasminogen activator (IV tPA) has been approved for treating acute ischemic stroke, it must be given within 3 hours of stroke onset and only after ruling out hemorrhagic stroke by computed tomography. Several medical centers are turning to angiography to guide intra-arterial infusion of thrombolytic agents and mechanical endovascular interventions.
